Timothy (Tim) Hunter tapped to provide strategic oversight of reimbursement strategies for TissueTech’s future biologics product pipeline.
Miami, Fla. – December 4, 2019 – TissueTech, Inc., a pioneer in the development and clinical application of regenerative human birth tissue products marketed through its subsidiaries Bio-Tissue, Inc. and Amniox Medical, Inc., announced today the appointment of Timothy Hunter to the position of Vice President, Reimbursement and Government Affairs to oversee enterprise-wide third-party payor and reimbursement activities.
In his new role, Tim will manage reimbursement and coverage issues related to Amniox and Bio-Tissue’s current product portfolios, including strategic work based upon reimbursement trends, coding and payment analysis, insurance authorization analysis, coverage analysis and the development of relationships with regional payers. In addition, he will be responsible for implementing the company’s strategic direction for coding and coverage and assisting with pricing strategies.
“Tim brings more than 20 years of biotechnology industry experience in both reimbursement and government affairs, and his proven track record made him the best candidate for this role,” said Amy Tseng, TissueTech President and Chief Executive Officer. “His vast experience in market access strategy and execution, health economics and reimbursement, payor education and coverage conversion, case-by-case denial appeals, longitudinal health economic analyses, facility value analyses, current and predictive payment models, specialty society coalition building, cross-functional team leadership, and biologics, human tissue, & medical device will be extremely valuable to our current and future product portfolios.”
Prior to joining TissueTech, Tim was Vice President, Health Economics, Reimbursement & Public Policy for Musculoskeletal Clinical Regulatory Advisers, LLC. Tim has held several other notable leadership roles throughout his career including: Manager, Health Policy and Reimbursement for Ortho Biotech, LP (now Janssen Biotech – a Johnson & Johnson Pharmaceutical Company) and Senior Associate for Covance Health Economics & Outcomes Services. Tim obtained his Master of Public Administration in Health Services Management & Policy and his Bachelor of Arts in Political Science & History from Syracuse University.
About TissueTech, Inc.
TissueTech, Inc., the parent company of Amniox Medical, Inc. and BioTissue, Inc., pioneered the development and clinical application of human placental tissue-based products. Founded in 1997, Bio-Tissue markets products for the ophthalmology and optometry markets; and Amniox markets products for use in the musculoskeletal and wound care markets. Clinicians have performed more than 500,000 human implants with the company’s products and published more than 360 peer-reviewed studies supporting its technology platform. The Company’s first product, AmnioGraft®, is the only tissue graft designated by the FDA to act as an anti-scarring, anti-inflammatory and anti-angiogenic agent and supporting epithelial adhesion and differentiation. Learn more at www.tissuetech.com.